Канал: AlphaMed Press

Advances in tissue engineering, bioprinting, and body-on-a-chip technologies

Advances in tissue engineering, bioprinting, and body-on-a-chip technologies

From Curriculum to Workforce: How to Bring Regenerative Medicine to Your Students

From Curriculum to Workforce: How to Bring Regenerative Medicine to Your Students

Webinar: Gaps and Opportunities for Fighting COVID-19

Webinar: Gaps and Opportunities for Fighting COVID-19

Webinar: Developing the Regenerative Medicine Workforce

Webinar: Developing the Regenerative Medicine Workforce

Stem Cell Research and Pay-to-Participate Trials Webinar

Stem Cell Research and Pay-to-Participate Trials Webinar

The Oncologist's Young Investigator Award - Alessio Cortellini, M.D., 2020 Recipient

The Oncologist's Young Investigator Award - Alessio Cortellini, M.D., 2020 Recipient

Publish in The Oncologist

Publish in The Oncologist

2020 STEM CELLS Journals Call for Applications - Young Investigator Award

2020 STEM CELLS Journals Call for Applications - Young Investigator Award

2014 Alpha Stem Cell Clinic Panel

2014 Alpha Stem Cell Clinic Panel

Dr. Benjamin Freedman | Stem Cells | 2018 Young Investigator Award Winner

Dr. Benjamin Freedman | Stem Cells | 2018 Young Investigator Award Winner

Rohan Kulkarni, Ph.D. STEM CELLS 2019 Young Investigator Award Winner

Rohan Kulkarni, Ph.D. STEM CELLS 2019 Young Investigator Award Winner

ArcLight Intensity

ArcLight Intensity

Adjuvant stroke treatment - do we need stem cells at all? Thorsten R. Doppner, MD, MSc

Adjuvant stroke treatment - do we need stem cells at all? Thorsten R. Doppner, MD, MSc

Dr Anna Krasnodembskaya | Stem Cells

Dr Anna Krasnodembskaya | Stem Cells

Cell Mechanosensitivity is Enabled by the LINC Nuclear Complex by Gunes Uzer, PD

Cell Mechanosensitivity is Enabled by the LINC Nuclear Complex by Gunes Uzer, PD

Dr. Philippe Lysy | Pediatric Endocrinologist | Stem Cells

Dr. Philippe Lysy | Pediatric Endocrinologist | Stem Cells

Statistical Considerations for Phase II Clinical Trials and Adaptive Designs

Statistical Considerations for Phase II Clinical Trials and Adaptive Designs

Publicly Funded Clinical Trials and Cancer Care

Publicly Funded Clinical Trials and Cancer Care

Gold Standard Task Force Report

Gold Standard Task Force Report

Update on the Role of Blood Transfusions

Update on the Role of Blood Transfusions

Project Data Sphere

Project Data Sphere

CEO Cancer Gold Standard Panel Discussion

CEO Cancer Gold Standard Panel Discussion

Prostate Cancer: Progress and Promise, Part III - Panel Discussion

Prostate Cancer: Progress and Promise, Part III - Panel Discussion

Plenary Discussion

Plenary Discussion

Patrick Johnson - Ethics in Clinical Research (Chinese)

Patrick Johnson - Ethics in Clinical Research (Chinese)

The White House Perspective

The White House Perspective

Richard Schilsky - Principal Investigator Responsibilities (Chinese)

Richard Schilsky - Principal Investigator Responsibilities (Chinese)

Lung Cancer: From Prevention to Cure

Lung Cancer: From Prevention to Cure

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring

Bacterial Genomics in Transplant-related Colitis

Bacterial Genomics in Transplant-related Colitis

McClay Lecture: A Parable Drawn from Phase 3 Metastatic Colorectal Cancer Trials

McClay Lecture: A Parable Drawn from Phase 3 Metastatic Colorectal Cancer Trials

Prospects for Targeted Therapy in Ovarian Cancer

Prospects for Targeted Therapy in Ovarian Cancer

Systematic studies of the histone methyl ‘ome’

Systematic studies of the histone methyl ‘ome’

Influence of anemia management on tumor progression: what do the data say?

Influence of anemia management on tumor progression: what do the data say?

CEO_Roundtable_2013_clip2_preview

CEO_Roundtable_2013_clip2_preview

Molecular Analysis of CTCs

Molecular Analysis of CTCs

Overview of the Use of Blood Transfusions in Different Clinical Settings

Overview of the Use of Blood Transfusions in Different Clinical Settings

Pinedo Prize Lecture: Individualized Breast Cancer Therapy

Pinedo Prize Lecture: Individualized Breast Cancer Therapy

Use of iron with ESAs and New insights to EPO receptor biology

Use of iron with ESAs and New insights to EPO receptor biology

CEO_Roundtable_2013_clip1_preview

CEO_Roundtable_2013_clip1_preview

The Importance of Cooperative Network for Clinical Trials in China (中文)

The Importance of Cooperative Network for Clinical Trials in China (中文)

Resistance in BRAF and KRAS Mutant Cancers

Resistance in BRAF and KRAS Mutant Cancers

Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells

Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells

Targeting Critical Oncogenic Pathways in Cancer

Targeting Critical Oncogenic Pathways in Cancer

Circulating Tumor Cells in Prostate Cancer - The Premise and the Promise

Circulating Tumor Cells in Prostate Cancer - The Premise and the Promise

Prostate Cancer Biomarkers in Context

Prostate Cancer Biomarkers in Context

Prostate Cancer: Progress and Promise - September, 2011: Roundtable Discussion

Prostate Cancer: Progress and Promise - September, 2011: Roundtable Discussion

Patrick Johnston - Challenges in Colorectal Cancer (Chinese)

Patrick Johnston - Challenges in Colorectal Cancer (Chinese)

Personalizing Cancer Drug Trials: The MGH Experience

Personalizing Cancer Drug Trials: The MGH Experience

2013 Bob Pinedo Cancer Care Keynote Lecture

2013 Bob Pinedo Cancer Care Keynote Lecture

Panel Discussion - Prostate Cancer - Progress and Promise, Part IV

Panel Discussion - Prostate Cancer - Progress and Promise, Part IV

Targeting Cancer Stem Cells for Durable Response

Targeting Cancer Stem Cells for Durable Response

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring (中

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring (中

Targeted Therapies for Breast Cancer

Targeted Therapies for Breast Cancer

Update on recent ESA and blood transfusion studies

Update on recent ESA and blood transfusion studies

Chromatin Modulators Provide a New Insight into Cancer Genomes

Chromatin Modulators Provide a New Insight into Cancer Genomes

Statistical Considerations for Phase II Trials and Adaptive Designs (中文)

Statistical Considerations for Phase II Trials and Adaptive Designs (中文)

EGFR Mutant Lung Cancer: 2013 Update

EGFR Mutant Lung Cancer: 2013 Update

The Genomic Architecture of Prostate Cancer

The Genomic Architecture of Prostate Cancer

Cancer Clinical Trials–Do We Need a New Algorithm in the Age of Stratified Medicine?

Cancer Clinical Trials–Do We Need a New Algorithm in the Age of Stratified Medicine?

Chairman's Panel: Progress ... and Promise

Chairman's Panel: Progress ... and Promise

CEO Report

CEO Report

Advances in Targeted Therapies for Lung Cancer

Advances in Targeted Therapies for Lung Cancer

Pharmacokinetics, Pharmacodynamics, and Identifying Adverse Events in Phase I Clinical Trials (中文)

Pharmacokinetics, Pharmacodynamics, and Identifying Adverse Events in Phase I Clinical Trials (中文)

Smart T Cell Vaccines: CAR T Cells

Smart T Cell Vaccines: CAR T Cells

Tailoring Treatment: Optimizing Outcomes With What is Available Now

Tailoring Treatment: Optimizing Outcomes With What is Available Now

Role of VEGFR and MET in Prostate Cancer

Role of VEGFR and MET in Prostate Cancer

Mr. Robert Wise

Mr. Robert Wise

IDH1 and other targets in metabolism

IDH1 and other targets in metabolism

Phase II Clinical Trials

Phase II Clinical Trials

Novel Therapies for Castration-Resistant Prostate Cancer

Novel Therapies for Castration-Resistant Prostate Cancer

Chairman’s Closing Remarks

Chairman’s Closing Remarks

EGFR mutation analysis

EGFR mutation analysis

Life Sciences Consortium Task Force – Drug Shortage Issue

Life Sciences Consortium Task Force – Drug Shortage Issue

Lillian Siu - Should We Enrich Patients in Phase I Trials (Chinese)

Lillian Siu - Should We Enrich Patients in Phase I Trials (Chinese)

ACT China II Roundtable

ACT China II Roundtable

Richard Schilsky - Phase II Clinical Trials (Chinese)

Richard Schilsky - Phase II Clinical Trials (Chinese)

Consolidation and Maintenance Therapy in Multiple Myeloma: What are the Options?

Consolidation and Maintenance Therapy in Multiple Myeloma: What are the Options?

You're in Charge: Principal Investigator Responsibilities

You're in Charge: Principal Investigator Responsibilities

A Coding-Independent Function of Gene and Pseudogene mRNAs Regulates Tumour Biology

A Coding-Independent Function of Gene and Pseudogene mRNAs Regulates Tumour Biology

Targeting of NSCLC in 2011

Targeting of NSCLC in 2011

Repurposing Drugs for Cancer Therapy

Repurposing Drugs for Cancer Therapy

Development and Validation of Biomarkers as Clinical Tests (中文)

Development and Validation of Biomarkers as Clinical Tests (中文)

Protein Methyltransferase Inhibitors as Personalized Cancer Therapeutics

Protein Methyltransferase Inhibitors as Personalized Cancer Therapeutics

Progress and Challenges Towards the Personalized Treatment of Prostate Cancer

Progress and Challenges Towards the Personalized Treatment of Prostate Cancer

Cancer Survivorship and the Young Breast Cancer Patient

Cancer Survivorship and the Young Breast Cancer Patient

Colon Cancer Stratification: The Good, The Bad, and The Ugly

Colon Cancer Stratification: The Good, The Bad, and The Ugly

Neuroblastoma Immunotherapy

Neuroblastoma Immunotherapy

Zebrafish screens for new melanoma targets

Zebrafish screens for new melanoma targets

v_amp_sctm_roundtable_0511-ipad

v_amp_sctm_roundtable_0511-ipad

Phase I Biomarker Driven Clinical Trials: Objectives, Design, Endpoints (中文)

Phase I Biomarker Driven Clinical Trials: Objectives, Design, Endpoints (中文)

Targeting the Androgen Receptor: Past, Present and Future

Targeting the Androgen Receptor: Past, Present and Future

Targeting activated ERK signaling in human tumors: Sensitivity and Resistance

Targeting activated ERK signaling in human tumors: Sensitivity and Resistance

SCLC: The next frontier in lung cancer therapy

SCLC: The next frontier in lung cancer therapy

Drug Discovery for Rare Diseases: The ACCRF Model

Drug Discovery for Rare Diseases: The ACCRF Model

Dot 1L a viable target for leukemia therapy

Dot 1L a viable target for leukemia therapy

Roundtable: The Growing Complexity of Treatment Choices and Strategies

Roundtable: The Growing Complexity of Treatment Choices and Strategies

v_stomeeting_roundtable_1110-ipad

v_stomeeting_roundtable_1110-ipad

Colon Cancer 2013 Why it’s hard to develop drugs

Colon Cancer 2013 Why it’s hard to develop drugs

Cancer through a stem cell lens

Cancer through a stem cell lens

Life Sciences Consortium Task Force Report

Life Sciences Consortium Task Force Report

Targeting the PI3K pathway in Breast Cancer

Targeting the PI3K pathway in Breast Cancer

Task Force Chairman's Report

Task Force Chairman's Report

Chairman’s Welcome

Chairman’s Welcome

Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment

Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment

Personalized Medicine: Do We Still Have to Treat Everyone the Same Way?

Personalized Medicine: Do We Still Have to Treat Everyone the Same Way?

"Click" Chemistry In Vivo - New Tools for Molecular Imaging

"Click" Chemistry In Vivo - New Tools for Molecular Imaging

Protons for Prostate Cancer: Beams, Dreams, Schemes and the Technology Arms Race

Protons for Prostate Cancer: Beams, Dreams, Schemes and the Technology Arms Race

Role of PSA for mCRPC patients after docetaxel

Role of PSA for mCRPC patients after docetaxel

You're in Charge: Principal Investigator Responsibilities (中文)

You're in Charge: Principal Investigator Responsibilities (中文)

Chairman's Welcome and Introduction of New Members

Chairman's Welcome and Introduction of New Members

Challenges in Colorectal Cancer

Challenges in Colorectal Cancer

Pancreatic Cancer Medicine

Pancreatic Cancer Medicine

The Alpha Stem Cell Clinic: A Model for Evaluating and Delivering Stem Cell-Based Therapies

The Alpha Stem Cell Clinic: A Model for Evaluating and Delivering Stem Cell-Based Therapies

Webcast

Webcast

In Vivo Evaluation of EGFR Mutational Status

In Vivo Evaluation of EGFR Mutational Status

Phase III Trial Design

Phase III Trial Design

BRAF: The First Prevalent Oncogene Target to Show Single-Agent Responsiveness

BRAF: The First Prevalent Oncogene Target to Show Single-Agent Responsiveness

PK, Drug-Target Interactions, and Identifying AE’s in Phase I Biomarker-Driven Trials

PK, Drug-Target Interactions, and Identifying AE’s in Phase I Biomarker-Driven Trials

Bone Directed Approaches and Imaging Biomarker

Bone Directed Approaches and Imaging Biomarker

High-risk Multiple Myeloma: Definitions and Treatment Considerations

High-risk Multiple Myeloma: Definitions and Treatment Considerations

New Prognostic Biomarkers

New Prognostic Biomarkers

Mutation Based Resistance to TKI Therapy

Mutation Based Resistance to TKI Therapy

Novel Strategies for Drug Development in Cancer: An Industry Perspective

Novel Strategies for Drug Development in Cancer: An Industry Perspective

Exosomes as Biomarkers for Brain Tumors

Exosomes as Biomarkers for Brain Tumors

Patrick Johnson - Ethics in Clinical Research (Stereo sound)

Patrick Johnson - Ethics in Clinical Research (Stereo sound)

The Use of Emerging Genomic Technologies to Predict Tumor Response and Drug Resistance

The Use of Emerging Genomic Technologies to Predict Tumor Response and Drug Resistance

Zebrafish as a Model for Human Cancer

Zebrafish as a Model for Human Cancer

Patients' Perspectives: John Patrick Michael Murphy

Patients' Perspectives: John Patrick Michael Murphy

The PI3K Pathway

The PI3K Pathway

TERT Promoter Mutations in Cancer

TERT Promoter Mutations in Cancer

Prediction of Response to Anthracycline-Based Chemotherapy in Early Breast Cancer

Prediction of Response to Anthracycline-Based Chemotherapy in Early Breast Cancer

Protein Methyl Transferases as a Novel Target Class for Molecularly Targeted Cancer Therapy

Protein Methyl Transferases as a Novel Target Class for Molecularly Targeted Cancer Therapy

Lung Cancer at the Advent of Targeted Therapy

Lung Cancer at the Advent of Targeted Therapy

Aromatase Inhibitors and Breast Cancer Therapy

Aromatase Inhibitors and Breast Cancer Therapy

ERBB3

ERBB3

Tony Mok - Phase III Trial Design (Chinese)

Tony Mok - Phase III Trial Design (Chinese)

Charles Hugh-Jones, MD, MRCP

Charles Hugh-Jones, MD, MRCP

Personalized Therapy for Advanced NSCLC

Personalized Therapy for Advanced NSCLC

The ALK Story, a New Kind of Phase I Trial

The ALK Story, a New Kind of Phase I Trial

Panel Discussion: Phase I Biomarker Driven Clinical Trials (中文)

Panel Discussion: Phase I Biomarker Driven Clinical Trials (中文)

Preserving Fertility in Young Women with Breast Cancer: Treatment Options

Preserving Fertility in Young Women with Breast Cancer: Treatment Options

Prostate Cancer: Progress and Promise Part V – Panel Discussion

Prostate Cancer: Progress and Promise Part V – Panel Discussion

Current anemia management guidelines: Update

Current anemia management guidelines: Update

PK, Drug-Target Interactions, and Identifying AE’s in Phase I Biomarker-Driven Trials (中文)

PK, Drug-Target Interactions, and Identifying AE’s in Phase I Biomarker-Driven Trials (中文)

Taxanes: Pivotal Agents in the Management of Metastatic Castrate-Resistant Prostate Cancer

Taxanes: Pivotal Agents in the Management of Metastatic Castrate-Resistant Prostate Cancer

Business Report

Business Report

Bridging Cell Cycle and Organismal Behavior Through Histone Demethylation

Bridging Cell Cycle and Organismal Behavior Through Histone Demethylation

Panel Discussion: Phase I Biomarker Driven Clinical Trials

Panel Discussion: Phase I Biomarker Driven Clinical Trials

DNA Repair: PARP, A Target in Evolution

DNA Repair: PARP, A Target in Evolution

Challenges in Oncology: From clinical trials to introducing new drugs to the clinic

Challenges in Oncology: From clinical trials to introducing new drugs to the clinic

16-keynote-tues-gilman

16-keynote-tues-gilman

The Oncologist_LinkedIn_App_Demo

The Oncologist_LinkedIn_App_Demo

Incorporating Biomarkers in Phase I Clinical Trials - Contribution to Phase II and III (中文)

Incorporating Biomarkers in Phase I Clinical Trials - Contribution to Phase II and III (中文)

Leveraging Genetically Engineered Mouse Models of Small Cell Lung Cancer for Advanced Therapeutic St

Leveraging Genetically Engineered Mouse Models of Small Cell Lung Cancer for Advanced Therapeutic St

Drug combination in melanoma: is more better?

Drug combination in melanoma: is more better?

Redefining Early Detection and Predicting Outcomes of Primary Treatment

Redefining Early Detection and Predicting Outcomes of Primary Treatment

Roundtable: Management of anemia in nephrology patients

Roundtable: Management of anemia in nephrology patients

Exploring the Complexities of Androgen Signaling in Prostate Cancer Progression

Exploring the Complexities of Androgen Signaling in Prostate Cancer Progression

Roundtable: Management of anemia in patients receiving chemotherapy

Roundtable: Management of anemia in patients receiving chemotherapy

Cancer Education and its Role in Cancer Care in Europe

Cancer Education and its Role in Cancer Care in Europe

Finding Biomarkers: Molecular Profiling and CTCs

Finding Biomarkers: Molecular Profiling and CTCs

Bone-Targeted Therapy for Prostate Cancer

Bone-Targeted Therapy for Prostate Cancer

Histone H3K27 Demethylases as a Therapeutic Target in Polysomy 21 Leukemia

Histone H3K27 Demethylases as a Therapeutic Target in Polysomy 21 Leukemia

Treatment of Frail Elderly Patients with Multiple Myeloma

Treatment of Frail Elderly Patients with Multiple Myeloma

Systemic Therapy for Advanced Prostate Cancer

Systemic Therapy for Advanced Prostate Cancer

Life Sciences Consortium: Task Force Report and Panel Discussion

Life Sciences Consortium: Task Force Report and Panel Discussion

Inflammatory Chemokines in Prostate Cancer: Where, What and When To Target?

Inflammatory Chemokines in Prostate Cancer: Where, What and When To Target?

Remarks by Elizabeth Fowler - Special Assistant to the President for Health Care and Economic Policy

Remarks by Elizabeth Fowler - Special Assistant to the President for Health Care and Economic Policy

Chairman’s report

Chairman’s report

ErbB3 in ovarian cancer

ErbB3 in ovarian cancer

Preserving Fertility in Young Women with Breast Cancer: Challenges and Advances

Preserving Fertility in Young Women with Breast Cancer: Challenges and Advances

Anti- PD1 Treatment in Advanced Melanoma

Anti- PD1 Treatment in Advanced Melanoma

Resistance to MAPK pathway inhibition in BRAF mutant colorectal cancers

Resistance to MAPK pathway inhibition in BRAF mutant colorectal cancers

Biomarker-Driven Drug Development from Dream to Reality

Biomarker-Driven Drug Development from Dream to Reality

Lillian Siu - Phase 1 Clinical Trials - Objectives Design and Endpoints (Chinese)

Lillian Siu - Phase 1 Clinical Trials - Objectives Design and Endpoints (Chinese)

Incorporating Biomarkers in Phase I Clinical Trials - Contribution to Phase II and III (中文)

Incorporating Biomarkers in Phase I Clinical Trials - Contribution to Phase II and III (中文)

Androgen Receptor Antagonists

Androgen Receptor Antagonists

Improving Overall Survival after Stem Cell Transplant

Improving Overall Survival after Stem Cell Transplant

Immune Biomarkers for Patients Selection in Immunotherapy of Prostate Cancer

Immune Biomarkers for Patients Selection in Immunotherapy of Prostate Cancer

A New Approach to Phase II/III Evaluation of Noval Therapies

A New Approach to Phase II/III Evaluation of Noval Therapies

Teatment options in high-risk disease and frail patients

Teatment options in high-risk disease and frail patients

The Art of Oncology

The Art of Oncology

Luo.v3.AudioRepaired

Luo.v3.AudioRepaired

Nominating Committee Report

Nominating Committee Report

Phase I Clinical Trials: Objectives, Design, and Endpoints

Phase I Clinical Trials: Objectives, Design, and Endpoints

Special Lecture: The Impact of Genomic and Signaling Research on Clinical Research

Special Lecture: The Impact of Genomic and Signaling Research on Clinical Research

Is Prostate Cancer Responsive to the Immune System?

Is Prostate Cancer Responsive to the Immune System?

ASCO2014_full_v1

ASCO2014_full_v1

MUC-1, biology and target for therapy

MUC-1, biology and target for therapy

Mr. Robert J. Mulroy

Mr. Robert J. Mulroy

Building Bridges to Conquer Cancer

Building Bridges to Conquer Cancer

Doug Pyle - Building Bridges to Conquer Cancer (Chinese)

Doug Pyle - Building Bridges to Conquer Cancer (Chinese)

Breast Cancer: New Treatments and Improved Therapies

Breast Cancer: New Treatments and Improved Therapies

Radionuclide Therapy in Prostate Cancer

Radionuclide Therapy in Prostate Cancer

Prognostication in Breast Cancer: Are We Smarter Yet?

Prognostication in Breast Cancer: Are We Smarter Yet?

Screening for Colon Cancer

Screening for Colon Cancer

Targeting the PI3K Pathway in the Therapy of Breast Cancer

Targeting the PI3K Pathway in the Therapy of Breast Cancer

MM Treatment Strategies – An European Perspective

MM Treatment Strategies – An European Perspective